Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005
Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Laramee P, Bell M, Irving A, Brodtkorb TH. The cost-effectiveness of the integration of nalmefene within the UK healthcare system treatment pathway for alcohol dependence. Alcohol Alcohol. 2016 May;51(3):283-90. doi: 10.1093/alcalc/agv140
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Petit A, Castillo M, Gaspa A, Colomer D, Garcia de Albeniz X, Moreno C, Camos M, Mellado B, Mallofre C. Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma. Histopathology. 2009 Aug;55(2):230-2. doi: 10.1111/j.1365-2559.2009.03342.x